Health
OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain
After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in neuropathic corneal pain (NCP), as measured by Visual Analogue Scale (VAS), demonstrating highly effective treatment.Urcosimod (0.05%) demonstrated a marked reduction in pain scores as early as Week 4, with sustained efficacy maintained throughout the trial.A statistically significant reduction in mean pain scores was observed from Visit 1 to the end of treatment Visit 4 (p-va
About this update from Okyo Pharma Limited
[{"type":"image","alt":"OKYO Pharma LTD","displaySize":"","headline":null,"caption":"OKYO Pharma LTD","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":113,"url":"https://media.zenfs.com/en/globenewswire.com/a8bd0cda50c593b9f86805333401781f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Z5rBQz17s3GxW5mY3tWfBg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a8bd0cda50c593b9f86805333401781f","width":300,"height":113}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in neuropathic corneal pain (NCP), as measured by Visual Analogue Scale (VAS), demonstrating highly effective treatment.","length":238,"tagName":"p"}]},{"val":[{"type":"text","content":"Urcosimod (0.05%) demonstrated a marked reduction in pain scores as early as Week 4, with sustained efficacy maintained throughout the trial.","length":141,"tagName":"p"}]},{"val":[{"type":"text","content":"A statistically significant reduction in mean pain scores was observed from Visit 1 to the end of treatment Visit 4 (p-value = 0.025) in the per-protocol 0.05% urcosimod group, indicating the drug’s effectiveness over the study period.","length":235,"tagName":"p"}]},{"val":[{"type":"text","content":"Notably, all these responders entered the study with moderate to severe NCP pain scores despite prior use of maximum medical therapy.","length":133,"tagName":"p"}]},{"val":[{"type":"text","content":"No serious adverse events were reported among the 18 patients throughout the trial.","length":83,"tagName":"p"}]},{"val":[{"type":"text","content":"Following completion of full data analysis, OKYO plans a meeting with FDA to discuss next steps for urcosimod which has already received Fast Track designation for treating NCP.","length":177,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1007,"olType":false},{"type":"text","content":"LONDON and NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, is pleased to announce po...